Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies
Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.
Read more